Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Neuroectodermal Tumors, Primitive 2Neoplasms 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Hamartoma Syndrome, Multiple 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × dactolisib × Clear all
NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT00620594 2020-12-09

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Novartis

Phase 1 Completed
183 enrolled
Breast

Breast Diseases, Breast Neoplasms, Hamartoma Syndrome, Multiple, Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01495247 2020-12-08

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Novartis

Phase 1/2 Terminated
18 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01288092 2012-06-07

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Novartis

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡